About: Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors
Creator	Loddo, Roberta Madeddu, Silvia Sanna, Giuseppina Aulic, Suzana Caria, Paola Carta, Antonio Corona, Paola Fermeglia, Maurizio Ibba, Roberta Laurini, Erik Piras, Sandra Pricl, Sabrina Désaubry, Laurent Costi, Maria Sadiq, Abdul
Source	PMC
abstract	Human Respiratory Syncytial Virus (RSV) is the primary cause of bronchopneumonia in infants and children worldwide. Clinical studies have shown that early treatments of RSV patients with ribavirin improve prognosis, even if the use of this drug is limited due to myelosuppression and toxicity effects. Furthermore, effective vaccines to prevent RSV infection are currently unavailable. Thus, the development of highly effective and specific antiviral drugs for pre-exposure prophylaxis and/or treatment of RSV infections is a compelling need. In the quest of new RSV inhibitors, in this work we evaluated the antiviral activity of a series of variously substituted 5,6-dichloro-1-phenyl-1(2)H-benzo[d][1,2,3]triazole derivatives in cell-based assays. Several 1- and 2-phenyl-benzotriazoles resulted fairly potent (μM concentrations) inhibitors of RSV infection in plaque reduction assays, accompanied by low cytotoxicity in human highly dividing T lymphoid-derived cells and primary cell lines. Contextually, no inhibitory effects were observed against other RNA or DNA viruses assayed, suggesting specific activity against RSV. Further results revealed that the lead compound 10d was active during the early phase of the RSV infection cycle. To understand whether 10d interfered with virus attachment to target cells or virus-cell fusion events, inhibitory activity tests against the RSV mutant strain B1 cp-52—expressing only the F envelope glycoprotein—and a plasmid-based reporter assay that quantifies the bioactivity of viral entry were also performed. The overall biological results, in conjunction with in silico modeling studies, supported the conclusion that the RSV fusion process could be the target of this new series of compounds.
has issue date	2019-04-16(xsd:dateTime)
bibo:doi	10.3389/fchem.2019.00247
bibo:pmid	31041309
has license	cc-by
sha1sum (hex)	48215f45ce10b06c8f96b087cf1d72de2b40662a
schema:url	https://doi.org/10.3389/fchem.2019.00247
resource representing a document's title	Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors
has PubMed Central identifier	PMC6476926
has PubMed identifier	31041309
schema:publication	Front Chem
resource representing a document's body	covid:48215f45ce10b06c8f96b087cf1d72de2b40662a#body_text
is schema:about of	named entity 'DERIVED' named entity 'LOW' named entity 'CELLS' named entity 'PLAQUE' named entity 'DUE TO' named entity '282' named entity 'ENVELOPE GLYCOPROTEIN' named entity 'RNA' named entity 'VIRUS ATTACHMENT' named entity 'IS A' named entity 'UNDERSTAND' named entity 'HUMAN RESPIRATORY SYNCYTIAL VIRUS' named entity 'SUPPORTED' named entity 'ANTIVIRAL ACTIVITY' named entity 'VIRAL ENTRY' named entity 'RSV' named entity 'INHIBITORY ACTIVITY' named entity 'BRONCHOPNEUMONIA' named entity 'RSV INFECTIONS' named entity 'REDUCTION' named entity 'PERFORMED' named entity 'PRIMARY' named entity 'BASED' named entity 'CONCLUSION' named entity 'DEVELOPMENT' named entity '2C6' named entity 'LYMPHOID' named entity 'STUDIES' named entity 'PHENYL' named entity 'fusion' named entity 'virus' named entity 'development' named entity 'Selective' named entity 'PHENYL' named entity 'SERIES' named entity 'LEAD COMPOUND' named entity 'IN SILICO' named entity 'BENZOTRIAZOLES' named entity 'PRE-EXPOSURE PROPHYLAXIS' named entity 'HUMAN' named entity 'PROCESS' named entity 'PROGNOSIS' named entity 'PATIENTS' named entity 'RESULTS' named entity 'FUSION' named entity 'MYELOSUPPRESSION' named entity 'TREATMENTS' named entity 'CELL FUSION' named entity '10D' named entity 'WORLDWIDE' named entity 'OVERALL' named entity 'TO PREVENT' named entity 'TARGET CELLS' named entity 'OBSERVED' named entity 'BIOLOGICAL' named entity 'COULD BE' named entity 'SPECIFIC' named entity '5B1' named entity 'TREATMENT' named entity 'WORK' named entity 'EARLY' named entity 'UNAVAILABLE' named entity 'INFANTS' named entity 'TESTS' covid:arg/48215f45ce10b06c8f96b087cf1d72de2b40662a named entity 'CLASS' named entity 'BENZOTRIAZOLES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software